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Abstract.
Background: Cerebral small vessel disease (SVD) and neuropsychiatric symptoms (NPS) independently increase the risk
of cognitive decline. While their co-existence has been reported in the preclinical stage of dementia, longitudinal data
establishing the prognosis of their associations, especially in an Asian context remains limited.
Objective: This study investigated the role of SVD and NPS progressions on cognitive outcomes over 2 years in a dementia-
free elderly cohort.
Methods: 170 dementia-free elderly with baseline and 2-year neuropsychological assessments and MRI scans were included
in this study. White matter hyperintensities (WMH), lacunes, and microbleeds (CMBs) were graded as markers of SVD.
The Neuropsychiatric Inventory (NPI) was used to measure NPS. Generalized estimating equations modelling evaluated the
relationship between NPI change and SVD progression. Logistic regression evaluated the risk of incident cognitive decline
with both SVD and NPS. All models were adjusted for demographics, baseline cerebrovascular diease, and medial temporal
lobe atrophy.
Results: Higher NPI scores were associated with higher SVD burden at baseline. Subjects with WMH progression had
greater increase in total NPI ([SE] = 0.46[0.19], p = 0.016), driven by hyperactivity subsyndrome ([SE] = 0.88[0.34],
p = 0.007). Subjects with incident CMBs had greater increase in psychosis subsyndrome ([SE] = 0.89[0.30], p < 0.001).
Subjects with progressions in both SVD and NPS were more likely to develop cognitive decline over 2 years (OR[95%
CI] = 4.17[1.06–16.40], p < 0.05).
Conclusion: Our findings support worsening of NPS as a clinical indicator of SVD progression and are associated with
cognitive decline over 2 years. Early detection of NPS and targeted interventions on SVD burden may improve NPS outcomes.
Keywords: Cerebral small vessel disease, cognitive impairment, dementia, lacune, microbleeds, neurobehavioral symptoms,
Neuropsychiatric Inventory, white matter hyperintensities
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INTRODUCTION
Cerebral small vessel disease (SVD), includ-
ing white matter hyperintensities (WMH), lacunar
infarcts, and cerebral microbleeds (CMBs), are indi-
cators of brain structural abnormalities involving the
small arteries, arterioles, venules, and capillaries of
the brain [1]. These lesions may represent various
ischemic, hemorrhagic, and inflammatory damages
and are frequently observed among older adults in
brain magnetic resonance imaging (MRI) [2]. SVD
is an established contributor to cognitive impair-
ment and dementia, especially in Asian populations
[3, 4].
Neuropsychiatric symptoms (NPS) of depres-
sion, apathy, disinhibition, and psychosis are related
to cognitive impairment, poorer quality of life,
increased caregiver burden, and early institutional-
ization [5–8]. Even in the absence of concurrent
cognitive impairment, NPS are associated with worse
prognosis and a higher risk of developing dementia
[9, 10]. Previous studies have shown cross-sectional
associations between SVD burden and delusions in
Alzheimer’s disease (AD) patients [11], between
lacunes and depressive symptoms in elderly patients
with silent strokes [12], and between microbleeds
and disinhibition among community-dwelling older
adults [13].
However, no longitudinal studies have investigated
a wide range of NPS in relation to all three SVD mark-
ers of WMH, lacune, and CMBs. It is also unclear
if the specific patterns of association between SVD
markers and NPS are independent of other brain
structural abnormalities, such as large vessel disease
and atrophy. Given the adverse outcomes of NPS, a
better understanding of the longitudinal relationships
between NPS, SVD, and cognitive function would
help identify at-risk individuals and enhance strate-
gies in disease prevention. In the present study, we
aim to examine, in a sample of dementia-free Asian
elderly from the memory clinic, 1) the association
between SVD and NPS at baseline; 2) the association
between SVD progression and longitudinal changes
in NPS; and 3) the interactive effect of SVD and NPS
on cognitive decline. We hypothesized that: 1) SVD
markers of WMH, CMBs, and lacune are associated
with NPS subsyndromes at baseline; 2) SVD pro-
gressions are associated with greater increase in the
severity of NPS at follow-up; and 3) progressions of




This study consisted of participants from an
ongoing prospective case-control study who were
recruited from the memory clinic at the National
University Hospital in Singapore. Subjects were con-
sidered eligible if they were aged 50 and above,
had sufficient language skills for neuropsycholog-
ical assessment, fulfilled diagnostic criteria [14],
and provided informed consent. Exclusion criteria
included diagnosis of dementia, major psychiatric
illness or substance abuse disorder, cognitive impair-
ment caused by a history of traumatic brain injury,
multiple sclerosis, tumor, epilepsy or systemic dis-
ease, and significant visual and auditory impairments.
Between August 2010 and December 2015, all sub-
jects underwent comprehensive evaluation including
clinical examination, neuropsychological and neu-
ropsychiatric assessments, and 3T brain MRI at
baseline and were followed up for two years (Fig. 1).
Ethics approval was obtained from the National
Healthcare Group Domain-Specific Review Board.
This study was conducted in accordance with the
Declaration of Helsinki. Written informed consent
was obtained in the preferred language of the partic-
ipants.
Clinical diagnosis
Patient diagnoses were made at weekly consen-
sus meetings, held among clinicians, psychologists,
and research personnel. Details of the assessments
and MRI scans were reviewed. Domain impairment
on a locally validated standardized neuropsycholog-
Fig. 1. Flowchart of study participants.
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ical battery (the vascular dementia battery, VDB)
[15] was defined as ≥ 1.5 standard deviations below
education-adjusted norms. Subjects who had no
objective cognitive impairment on the VDB or func-
tional impairment, yet with or without subjective
cognitive impairment, were diagnosed as no cog-
nitive impairment (NCI). In the present study, 11
(17.2%) NCI participants had subjective cognitive
impairment. Subjects with subjective complaints and
objective impairment on at least one cognitive domain
on the VDB but functionally independent, hence not
meeting DSM-IV for dementia, were diagnosed as
mild cognitive impairment (MCI) [16]. Dementia
cases were diagnosed according to DSM-IV criteria
and were excluded from this study.
Assessment of neuropsychiatric symptoms
Suitable informants with frequent interactions with
the study subjects for at least 10 hours a week were
administered the 12-item Neuropsychiatric Inventory
(NPI) [17] at both visits. The NPI is a structured
interview which investigates the presence, frequency,
severity, and caregiver distress of 12 behavioral and
psychological symptoms. For each symptom, the
informant was asked whether the behavior had been
present in the past month and if it was a change from
the subject’s usual behavior. A total score for each
symptom was derived by multiplying the frequency
and severity of the symptom and the total NPI score
was the sum of all individual symptom scores. Sub-
sequently, individual symptoms were classified into
four subsyndromes as suggested by the European
Alzheimer’s Disease Consortium [18, 19]:
1. Hyperactivity (agitation, elation, disinhibition,
irritability, and aberrant motor behaviors);
2. Psychosis (delusions, hallucinations, and night-
time behaviors);
3. Affective symptoms (depression and anxiety);
4. Apathy (apathy and appetite/eating behaviors).
The score for each subsyndrome was the sum of
all symptom scores in the subsyndrome.
Neuroimaging
MRI scans were performed on a 3-T Siemens Mag-
netom Trio Tim Scanner, with a 32 -channel head
coil at the Clinical Imaging Research Center of the
National University of Singapore. The standardized
neuroimaging protocol included three-dimensional
(3D) T1-weighted, T2-weighted, fluid-attenuated
inversion recovery (FLAIR), susceptibility weighted
images (SWI) sequence and a 3D time of flight mag-
netic resonance angiography (TOFMRA). Identical
MRI protocol and scanner were used for baseline and
year-2 visits. MRI markers of cerebrovascular disease
were graded based on the Standards for Reporting
Vascular changes on Neuroimaging (STRIVE) crite-
ria [20]:
• Lacunes were defined as round or ovoid lesions
involving the subcortical regions, 3 to 15 mm
in diameter, with a low signal on T1-weighted
images and FLAIR, a high signal on T2-weighted
images and a hyperintense rim with a cen-
tre following the cerebrospinal fluid intensity
[20]. Total number of lacunes were counted
and ≥ 1 lacune was labelled as the presence of
any lacune. Lacunes were differentiated from
enlarged perivascular spaces, which are lesions
that are well defined, round, ovular or tubular in
shape with a smooth margin, less than 5 mm in
size, and in the absence of a hyperintense rim [21].
• CMBs were defined as focal, round hypointense
lesions with blooming effect on SWI and graded
using the Microbleed Anatomical Rating Scale
(MARS) [22]. As a threshold effect of multiple
CMBs (≥2 CMBs) was previously reported on
clinically relevant symptoms [13, 23, 24], the total
number of CMBs were counted and ≥ 2 CMBs
was labelled as the presence of multiple CMBs.
• WMH was defined as hyperintense on T2
and FLAIR sequences and hypointense on T1-
weighted images. WMH was graded using the
Modified Fazekas Scale (absent = 0, punctate = 1,
early confluent = 2, and confluent = 3) [25] and
a score of ≥ 2 was labelled as having moderate-
severe WMH [26].
Progressions of SVD were assessed by compar-
ing baseline and year-2 scans. Progression of WMH
was graded using the Modified Rotterdam Progres-
sion Scale [27] and labelled as presence or absence
of WMH progression. The presence of multiple new
CMBs (>1) seen on year-2 scans which were absent
on baseline scans was labelled as having incident
multiple CMBs [28]. The presence of any new lacune
seen on year-2 scans which were absent on base-
line scans was labelled as having incident lacune
[28]. Subjects with regression of CMBs (n = 7) were
included in the group without incident CMBs. No
subjects had a regression for WMH or lacunes.
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In addition, cortical infarcts [20] and intracra-
nial stenosis [29] were graded as markers of
large vessel disease. The severity of medial tem-
poral lobe atrophy (MTA) was also assessed and
was graded on coronal sections using the Schel-
tens’ Scale (0 = normal, 1 = mild, 2 = mild-moderate,
3 = moderate, 4 = severe) [30, 31] and a MTA score
of ≥ 2 was labelled as having significant MTA. All
MRI scans were graded by one rater (B.G.) who was
blinded to the clinical history of the subjects and
confirmed by an experienced fellow (S.H.). Good-to-
excellent intra-rater agreement of all MRI markers
was showed by the intra-class correlation coeffi-
cients, which are detailed elsewhere [28].
Demographics and vascular risk profile
All subjects were administered a detailed question-
naire to collect information on age, gender, years of
formal education, and ethnicity. Vascular risk profile
was obtained for all subjects through clinical inter-
view, physical examination, and review of laboratory
and medical records. This included hypertension,
defined as systolic blood pressure ≥ 140 mmHg
and/or diastolic blood pressure ≥ 9 0mmHg or the
use of antihypertensive medication; hyperlipidemia,
defined as total cholesterol level ≥ 4.14 mmol/l or the
use of lipid-lowering medication; diabetes mellitus,
defined as glycated hemoglobin ≥ 6.5% or the use of
antidiabetic medication; heart disease, defined as a
previous diagnosis of myocardial infarction, conges-
tive heart failure, atrial fibrillation, or intervention
procedures such as angioplasty, or stenting; and his-
tory of smoking (ever/never).
Outcome measures
All subjects underwent a standardized clinical
examination and neuropsychological assessments at
baseline and year-2 follow-up and were classified if
they had any baseline and progression of SVD and/or
NPS. Incident cognitive decline was defined as con-
version from NCI to MCI, or from MCI to dementia,
from baseline to year-2.
Statistical analysis
Cross-sectional associations of SVD markers
(moderate-severe WMH, multiple CMBs, and
lacune) with NPI scores at baseline were assessed
using generalized linear modelling, adjusting for
demographics, Clinical Dementia Rating (CDR)
score, vascular risk factors, significant MTA (n = 20),
and the presence of large vessel disease markers. Lon-
gitudinal analyses of NPI scores with progression of
SVD markers were examined using generalized esti-
mating equations (GEE) modelling. The differential
rates of change in NPI scores as a function of baseline
and progression of SVD were examined by apply-
ing a marker × time interaction effect in the GEE
models, adjusting for demographics, time, baseline
CDR score, small and large vessel disease markers,
total NPI score, and significant MTA. The effects
of incident lacune were not examined due to the
low occurrence in this sample (n = 5). Subsequently,
the likelihood of incident cognitive decline at year-2
was examined using logistic regression analysis with
95% confidence interval (CI), adjusting for demo-
graphics, baseline CDR, total NPI score, large vessel
disease markers, and significant MTA. All analyses
were performed using SPSS version 25 software, and
statistical significance was determined as two-tailed p
value < 0.05. Bonferroni correction was performed to




A total of 235 dementia-free subjects who com-
pleted baseline and year-2 visits were recruited in
this study. Four who did not perform MRI scans
due to medical conditions and another 61 without
NPI assessment at year-2 were excluded, leaving a
total of 170 subjects (64 NCI, 106 MCI) for the
final analysis. Other than being older (73.3 ± 7.2 ver-
sus 69.5 ± 7.3, p < 0.01), excluded subjects (n = 65)
did not differ from included subjects in demograph-
ics, diagnosis, clinical features, cognitive scores,
neuropsychiatric profile, and MRI findings (all
ps > 0.05). Characteristics of the current sample were
summarized in Table 1. Figure 2 shows the frequen-
cies of the four NPS subsyndromes at baseline and
year-2.
Baseline associations of SVD with NPS
As shown in Fig. 3, the presence of moderate-
severe WMH ( [SE] = 1.12 [0.27], p < 0.001) and
multiple CMBs ( [SE] = 0.82 [0.29], p = 0.005)
were associated with higher total NPI scores at
baseline. Subjects with moderate-severe WMH had
higher hyperactivity ( [SE] = 1.22 [0.38], p = 0.001)
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Table 1
Characteristics of Study Sample
All
Characteristics (n = 170)
Baseline Demographics & risk factors
Age, M (SD) 69.5 (7.3)





Education, 0–6 years, n (%) 66 (38.8)
Hypertension, yes, n (%) 111 (65.3)
Diabetes, yes, n (%) 49 (28.8)
Hyperlipidemia, yes, n (%) 128 (75.3)
Smoking history, yes, n (%) 45 (26.5)
Heart disease, yes, n (%) 25 (14.7)
ApoE4 status, positive, n (%) 40 (23.5)
Baseline Cognitive profile
Baseline MMSE, M (SD) 25.7 (3.0)
Baseline MoCA, M (SD) 22.5 (4.1)
CDR global 0.5, n (%) 83 (48.8)
Baseline Neuropsychiatric symptoms, M (SD)
Total score 1.3 (3.3)
Hyperactivity 0.5 (1.8)
Psychosis 0.3 (1.2)
Affective symptoms 0.1 (0.7)
Apathy 0.3 (1.4)
SVD markers, n (%)
Baseline
Presence of moderate-severe WMH 87 (51.2)
Presence of multiple CMBs 34 (20.0)
Presence of any lacune 55 (32.4)
Progression
Presence of WMH progression 95 (55.9)
Presence of multiple incident CMBs 13 (7.6)
Presence of incident lacune 5 (2.9)
Other cerebrovascular disease markers, n (%)
Presence of cortical stroke 22 (12.9)
Presence of intracranial stenosis 24 (14.1)
MMSE, Mini-Mental State Examination; MoCA, Montreal Cog-
nitive Assessment; CDR, Clinical Dementia Rating, SVD, small
vessel disease; WMH, white matter hyperintensities; CMB, cere-
bral microbleed.
Fig. 2. Bar graph of the frequency of NPS subsyndromes at base-
line and year-2.
Fig. 3. Associations between SVD markers and total NPS severity
at baseline.
and apathy ( [SE] = 2.50 [0.64], p < 0.001) subsyn-
dromes. Subjects with multiple CMBs had higher
psychosis ( [SE] = 1.57 [0.49], p = 0.001) and affec-
tive symptoms ( [SE] = 1.79 [0.62], p = 0.004). The
presence of any lacune was associated with higher
apathy subsyndrome ( [SE] = 0.94 [0.45], p = 0.038)
but the association did not reach significance after
Bonferroni correction (p > 0.0125).
Longitudinal associations of SVD with changes
in NPS severity
Significant increase in total NPI score was
observed among subjects between baseline and
year-2 (mean difference = 0.72, 95% CI = 0.56–0.94,
p < 0.001). Having any lacune at baseline was associ-
ated with a higher increase in affective symptoms (
[SE] = 0.91 [0.24], p < 0.001). No other baseline SVD
markers were significantly associated with changes in
NPI scores (Table 2). After controlling for covariates
including baseline cognitive status, NPI score, and
MRI markers, subjects with WMH progression had
a greater increase in total NPI score ( [SE] = 0.46
[0.19], p = 0.0160), particularly in the hyperactiv-
ity subsyndrome ( [SE] = 0.88 [0.34], p = 0.0007)
(Table 3). In addition, subjects with incident
multiple CMBs had a greater increase in the psy-
chosis subsyndrome ( [SE] = 0.89 [0.30], p < 0.001)
(Table 3).
Incident cognitive decline in the presence of SVD
and/or NPS
At year-2, 11 NCI subjects (6.5%) developed inci-
dent MCI and 10 MCI subjects (5.9%) developed
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Table 2
Associations of Baseline SVD with Changes in Neuropsychiatric Symptoms
Neuropsychiatric Subsyndromes
Total NPI Hyperactivity Psychosis Affective Apathy
Baseline SVD markers  (SE)  (SE)  (SE)  (SE)  (SE)
Moderate-severe WMH
Model 1 0.21 (0.17) 0.24 (0.29) 0.09 (0.22) 0.53 (0.39) 0.01 (0.31)
Model 2 0.01 (0.18) –0.13 (0.35) –0.19 (0.43) 0.50 (0.34) 0.03 (0.32)
Multiple CMBs
Model 1 0.07 (0.19) –0.04 (0.27) 0.25 (0.26) 0.70 (0.32) –0.05 (0.29)
Model 2 0.06 (0.20) –0.07 (0.28) 0.24 (0.26) 0.68 (0.33) 0.05 (0.31)
Any lacune
Model 1 –0.32 (0.18) 0.05 (0.22) –0.61 (0.28) 0.91 (0.25)** –0.76 (0.29)
Model 2 –0.32 (0.18) 0.07 (0.22) –0.54 (0.25) 0.91 (0.24)** –0.79 (0.30)
Model 1: controlled for age, gender, CDR score, time, baseline NPS score, other baseline small and large vessel disease
markers (moderate-severe WMH, multiple CMBs, lacune, cortical infarct, intracranial stenosis), and significant MTA. Model
2: additionally controlled for markers of SVD progression (WMH progression, incident CMBs, incident lacune). **p < 0.0125.
Table 3
Associations of SVD Progression with Changes in Neuropsychiatric Symptoms
Neuropsychiatric Subsyndromes
Total NPI Hyperactivity Psychosis Affective Apathy
SVD markers  (SE)  (SE)  (SE)  (SE)  (SE)
WMH progression
Model 1 0.47 (0.19)* 0.89 (0.34)** 0.43 (0.23) 0.05 (0.33) –0.02 (0.36)
Model 2 0.46 (0.19)* 0.88 (0.34)** 0.37 (0.25) 0.04 (0.32) –0.01 (0.35)
Multiple incident CMBs
Model 1 0.31 (0.23) 0.24 (0.28) 0.94 (0.32)** 0.09 (0.52) –0.32 (0.42)
Model 2 0.21 (0.22) 0.13 (0.26) 0.89 (0.30)** 0.16 (0.54) –0.33 (0.44)
Model 1: controlled for age, gender, CDR score, time, baseline NPS score, baseline small and large vessel disease markers
(moderate-severe WMH, multiple CMBs, lacune, cortical infarct, intracranial stenosis), and significant MTA. Model 2: additionally
controlled for other markers of SVD progression (WMH progression, incident CMBs, incident lacune). **p < 0.0125, *p < 0.05.
Table 4
Odds Ratio (OR) of Incident Cognitive Decline
Factors OR (95% CI)
Baseline
Only SVD (n = 80) 2.19 (0.54–8.87)
Only NPS (n = 8) 2.33 (0.17–32.09)
Both SVD and NPS (n = 32) 2.04 (0.26–16.17)
Progression
Only SVD progression (n = 68) 0.81 (0.21–3.18)
Only NPS progression (n = 11) 2.29 (0.32–16.54)
Both SVD and NPS progressions (n = 27) 4.17 (1.06–16.40)*
Controlled for age, gender, education, baseline CDR, baseline total
NPS score, baseline presence of large vessel disease markers, and
significant MTA. *p < 0.05.
dementia. Decliners were less educated (61.9% ver-
sus 35.6% with 0–6 years of education, p = 0.02) and
had more severe WMH at baseline (71.4% versus
48.3% with moderate-severe WMH, p = 0.047). Nei-
ther the presence of SVD nor NPS alone predicted
cognitive decline independently. However, subjects
having progressions in both SVD and NPS had a
4-times higher odds of decline (Odds Ratio [95%
CI] = 4.17 [1.06–16.40], p < 0.05) (Table 4).
Sensitivity analysis
Sensitivity analyses were performed using GEE
models for the loss of NPI data at year-2 (data loss
ratio = 26.4%). In model 1, any subject with a miss-
ing value for total NPI score at year-2 was assigned
the lowest score from baseline; in model 2, any sub-
ject with a missing value for total NPI score at year-2
was assigned the highest score from baseline. In both
models, GEE analyses did not show significant asso-
ciation (p > 0.05) between changes in total NPI score
and baseline SVD markers, WMH progression, or
multiple incident CMBs (data not shown).
DISCUSSION
This study examined the association of SVD pro-
gression with worsening of NPS, and their interaction
on long-term clinical outcomes, in a dementia-free
Asian elderly sample over 2 years. We determined
that SVD burden was associated with a higher NPS
score at baseline, and the progressions of SVD was
associated with increase in the severity of NPS.
C.N. Kan et al. / SVD and NPS Progressions in Cognitive Decline 1059
Notably, we found that subjects having progres-
sions of both SVD and NPS were more likely to
develop incident cognitive decline. Our findings will
have important implications on the clinical man-
agement of dementia-free elders with worsening
of NPS.
Our cross-sectional results are in line with pre-
vious studies, which have consistently reported an
association between SVD and apathy, depressive
symptoms, and disinhibition in dementia-free elderly
samples [13, 32–34]. Moreover, the present study has
extended existing findings by exploring distinctive
associations between neurobehavioral patterns and
different SVD lesions. We identified the associations
of WMH with more severe hyperactivity and apathy,
and CMBs with more severe psychosis and affec-
tive symptoms at baseline. Our longitudinal results
also demonstrated the persistence of such associa-
tion, through a concurrent worsening of hyperactivity
in the presence of WMH progression and worsen-
ing of psychosis in the presence of multiple incident
CMBs.
Symptoms of hyperactivity are commonly found
in patients with WMH [35, 36]. It has been pro-
posed that WMH disrupts neuronal network of the
fronto-subcortical circuits through cerebral hypoper-
fusion, affecting normal function of decision-making
and complex behavior, which lead to the occurrence
of emotional and behavioral dysregulations [35, 37,
38]. As neuropsychiatric disturbances are associated
with disruptions of the dopaminergic and cholinergic
neurotransmitter circuit, WMH in the fronto-straital
and limbic regions may also be implicated in mood
and behavioral disinhibition [32].
The manifestation of psychosis may be produced
by CMBs, which are superparamagnetic hemosiderin
deposits [23], through disrupted electrical activity
leading to distributed neuronal dysfunction in the
frontal, subcortical, and parietal regions [39–42].
It was suggested that CMBs located in the deep
regions, such as basal ganglia, thalamus, brainstem,
and cerebellum, are related to disrupted atheroscle-
rotic microvessels linked to hypertension while lobar
CMBs, such as those occurring in the temporal lobe
and occipital lobe, are related to amyloid angiopathy
underlying AD pathology [43]. Although previous
studies have found a preliminary association between
disinhibition with lobar CMBs but not with deep
CMBs [13], data on the relationship between CMBs
and NPS is scarce. Therefore, future studies could
investigate the role of CMBs and their locations on
neuropsychiatric patterns to better understand the
potential mechanisms underlying CMBs and psy-
chotic symptoms.
In addition to our team’s previous finding that
WMH progression is associated with cognitive and
functional decline overtime [28], we further demon-
strated that having progressions of both SVD and
NPS presented an elevated risk of developing MCI
or dementia. In this study, 6.5% of NCI subjects
developed incident MCI and 5.9% of MCI patients
progressed to dementia. This rate is consistent with
other studies which reported comparable rates of
conversion (5–10%) over a period of 4 to 10 years
[44–46]. As increasing attention has been paid to
associate NPS as a risk factor of dementia [10],
which may be mediated by SVD, early detection and
management of these symptoms is therefore critical
to improving disease outcome. The current findings
may also guide clinicians in targeting SVD burden in
clinical intervention, such as cardiovascular risk man-
agement, particularly in the earliest stage, as NPS are
often not recognized until they become too disruptive
to the patients and their caregivers.
Interestingly, the present study showed that only
progressions of SVD are significantly associated with
worsening of NPS in the long-term, whereas most
baseline SVD markers did not predict changes in
NPS over time. This may be due to the initially
low SVD burden in a largely healthy dementia-free
sample (51.2% of subjects had a CDR score of 0),
in which 34.1% had no SVD, 35.3% had only one
SVD marker, 23.5% had two markers, and only 7.1%
had all three markers. While previous studies have
reported significant effects of SVD progressions par-
ticularly on increased depressive symptoms [38, 47,
48], we did not observe significant associations with
affective subsyndrome in this study. This discrepancy
could be due to the differences in scales for depres-
sion assessment and sample characteristics. On the
other hand, the presence of depressive symptoms may
have been masked by other symptoms that were not
assessed by the NPI.
There are limitations to this study. First, the current
findings do not reflect causation as the temporal rela-
tionship could not be determined. Second, as subjects
were recruited from the memory clinic, our findings
may not be generalizable to other samples. Third, the
limited sample size has prevented us from examin-
ing the neurobehavioral correlates of region-specific
SVD, such as lobar and deep CMBs, which are
suggested to underlie different pathologies. Fourth,
the current associations may be explained by non-
vascular factors such as AD pathology. Although
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this study controlled for significant MTA as a sur-
rogate marker of neurodegeneration, MTA may also
be caused by other vascular processes or neurode-
generative diseases. Further studies could examine
the influence of other AD biomarkers such as amy-
loid or tau burden. Fifth, we did not examine enlarge
perivascular spaces (EPVS), which have emerged as
another feature of SVD. However, EPVS may be non-
pathogenic as they can occur in normal aging and are
not associated with other MRI markers of SVD or
cognitive function [49, 50].
Strengths of this study include the use of a lon-
gitudinal design to follow up on an elderly sample
with a spectrum of cognitive status; availability of
repeated and comprehensive investigations includ-
ing MRI scans, neuropsychological assessments, and
NPI to assess a broad range of behavioral and psycho-
logical symptoms of dementia; focus on older adults
at a pre-dementia stage; and robustness of the analy-
sis which took into account the confounding effects
of vascular risk factors, neurodegeneration, and other
large vessel disease markers.
Conclusion
In conclusion, the current associations between
the progression of SVD, increasing severity of NPS,
and worse cognitive performance provide valuable
insight into the neurobiological correlates of NPS
that could impact on current clinical management
of NPS. As NPS are associated with specific SVD
pathophysiology and maybe an early manifestation
of dementia, early detection and management of SVD
may improve NPS and possibly prevent or delay dis-
ease progression. SVD burden may be one of the
factors to be targeted for clinical trial and manage-
ment strategies to improve NPS outcome.
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